The compound (67) exhibited synergistic antitumor activity when combined with irinotecan in MCF-7 and SW620 cancer cell lines, significantly enhancing the cytotoxic response and exhibiting dose-dependently inhibit the ATM signalling pathway by reducing the expression levels of phosphorylated ATM and phosphorylated p21. The gene discussed is ATM; the disease is cancer.